Table 3.

BRAF mutational status as a predictor of response and survival with anti-EGFR therapy.

Study	* BRAF status exon 15 codon 600	n	Treatment	RR		PFS		OS
				%	p value $	Median (months)	p value $	Median (months)	p value $
Di Nicolantonio et al. [2008]	BRAF mut	11	(Cetuximab or panitumumab) ± chemotherapy	0	0.029	NR	0.011	NR	<0.0001
	BRAF wt	68		3
Laurent-Puiget al. [2009]	BRAF mut	5	Cetuximab ± chemotherapy	0	0.063	1.8	0.001	6.5	0.001
	BRAF wt	110		46.8		7.2		14.8
European consortium De Roock et al. [2010]	BRAF mut	24	Cetuximab ± chemotherapy	8.3	0.0012	1.8	<0.0001	6.0	<0.0001
	BRAF wt	326		38.0		6.0		12.5
Bokemeyer et al. [2012]	BRAF mut	32	Chemotherapy/cetuximab	21.9	0.46	7.1	0.23	14.1	0.076
		38	Chemotherapy	13.2		3.7		9.9
	BRAF wt	349	Chemotherapy/cetuximab	60.7	<0.0001	10.9	<0.0001	24.8	0.048
		381	Chemotherapy	40.9		7.7		21.1
Tveit et al. [2012]	BRAF mut	55	NA	20	<0.001	5.1	<0.001	9.5	<0.001
	BRAF wt	402		50		8.3		22.0
PRIME Douillard et al. [2013]	BRAF mut	24	FOLFOX4/panitumumab	NA	NA	6.1	0.12	10.5	0.76
		29	FOLFOX4			5.4		9.2
	BRAF wt	228	FOLFOX4/panitumumab	NA	NA	10.8	0.002	28.3	0.02
		218	FOLFOX4			9.2		20.9
20050181 Peeters et al. [2014]	BRAF mut	22	FOLFIR/panitumumab	NA	NA	2.5	0.34	4.7	0.20
		23	FOLFIRI			1.8		5.7
	BRAF wt	186	FOLFIR/panitumumab	NA	NA	6.9	0.006	18.7	0.15
		190	FOLFIRI			5.5		15.4

^*All RAS wildtype. $Compared to row immediately below.

Chemo, chemotherapy; EGFR, epidermal growth factor receptor; NA, not available; NR, not reached; mut, mutation; OS, overall survival; PFS, progression-free survival; RR, relative risk; wt, wildtype.